Core Viewpoint - I-Well Bio (300357) has announced the completion of a Phase I clinical trial for its "house dust mite film agent," demonstrating safety and tolerability in adult patients with dust mite allergic rhinitis [1] Group 1: Clinical Trial Details - The clinical trial was randomized, double-blind, placebo-controlled, and involved dose escalation [1] - The study evaluated various maintenance doses ranging from 150 BU to 2700 BU, all of which are deemed suitable for Phase II clinical research [1] - Researchers plan to further explore the efficacy and safety of these doses by extending the administration period and increasing the sample size [1]

Core Viewpoint - The company has completed a Phase I clinical trial for its "house dust mite film agent," demonstrating good safety and tolerability in adult patients with dust mite allergic rhinitis in China [1] Group 1: Clinical Trial Results - The clinical trial was randomized, double-blind, placebo-controlled, and involved dose escalation [1] - Safety analysis indicated that all maintenance dose groups (150BU-2700BU) showed good safety, with adverse events classified as grade 1-2, and no serious adverse events or events leading to withdrawal were reported [1] Group 2: Immune Response Indication - Exploratory analysis revealed an upward trend in specific IgE and IgG4 levels related to house dust mites in the treatment groups compared to baseline, suggesting that continuous administration for 28 days may have induced an immune response [1]

证券代码：300357 证券简称：我武生物 公告编号：2026-002 浙江我武生物科技股份有限公司 关于取得屋尘螨膜剂 I 期临床试验总结报告的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 日前，浙江我武生物科技股份有限公司（以下简称"公司"）研发的"屋尘 螨膜剂"（以下简称"本品"）完成了一项"在中国成人尘螨变应性鼻炎患者中 舌下含服'屋尘螨膜剂'的安全性和耐受性临床研究——随机、双盲、安慰剂对 照、剂量递增的 I 期临床试验"，并取得了 I 期临床试验总结报告。现将有关内 容公告如下： 一、基本情况 产品名称：屋尘螨膜剂 注册分类：治疗用生物制品1类 二、试验结果 安全性分析结果显示，屋尘螨膜剂各维持剂量组（150BU-2700BU）的安全 性良好，发生的不良事件均为1~2级，未发生严重不良事件和导致退出的不良事 件。发生的不良反应主要为变应性鼻炎、口腔感觉减退、咽喉刺激、舌水肿、舌 痒、耳瘙痒等，均为局部不良反应。探索性分析结果显示，屋尘螨膜剂各剂量组 试验组的屋尘螨特异性IgE和屋尘螨相关组分特异性IgG4的水平相比基线均出现 上升趋势，提示 ...

Core Viewpoint - Iwubio experienced a decline of 0.58% in stock price on January 15, with a trading volume of 173 million yuan, indicating a potential shift in investor sentiment and market dynamics [1] Financing Summary - On January 15, Iwubio had a financing buy amount of 14.90 million yuan and a financing repayment of 36.21 million yuan, resulting in a net financing outflow of 21.31 million yuan [1] - The total financing and securities balance for Iwubio as of January 15 is 430 million yuan, which accounts for 2.66% of its market capitalization, indicating a relatively high financing balance compared to the past year [1] - The company had a securities lending repayment of 1,500 shares on January 15, with no shares sold, and a remaining securities lending balance of 11,300 shares valued at 349,100 yuan, which is low compared to the past year [1] Business Performance - As of September 30, Iwubio reported a total of 32,400 shareholders, a decrease of 6.22% from the previous period, while the average circulating shares per person increased by 6.63% to 14,927 shares [2] - For the period from January to September 2025, Iwubio achieved an operating income of 853 million yuan, representing a year-on-year growth of 16.86%, and a net profit attributable to shareholders of 345 million yuan, reflecting a growth of 26.67% [2] Dividend and Shareholding Information - Since its A-share listing, Iwubio has distributed a total of 965 million yuan in dividends, with 369 million yuan distributed over the past three years [3] - As of September 30, 2025, among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 5.56 million shares, an increase of 1.45 million shares from the previous period [3] - New institutional shareholders include Jiashi Mutual Fund and Penghua Medical Technology Fund, holding 4.71 million shares and 4.30 million shares respectively, while the China Merchants National Bio-Medical Index Fund reduced its holdings by 783,300 shares [3]

（文章来源：证券日报） 证券日报网讯 1月15日，我武生物在互动平台回答投资者提问时表示，公司是一家专业从事过敏性疾病 诊断及治疗产品的研发、生产和销售的高科技生物制药企业。公司研发人员可以借助各类大语言模型检 索相关研发信息和资料，公司药品的研发进展可以关注公司的定期报告与相关临时公告。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股东会审议通过利润分配方案的情况 1、浙江我武生物科技股份有限公司（以下简称"公司"）2025年第三季度权 益分派方案已获2025年12月24日召开的公司2025年第二次临时股东会审议通过， 以公司总股本523,584,000股为基数，向全体股东每10股派1.00元人民币现金（含 税），预计共计派发现金股利人民币52,358,400.00元（含税），不送红股，不进行 资本公积金转增股本。若在分配方案实施前，出现股权激励行权、可转债转股、 股份回购等公司股本总额发生变动情形的，将按照分红总金额固定不变的原则， 调整计算分配比例。 证券代码：300357 证券简称：我武生物 公告编号：2026-001 浙江我武生物科技股份有限公司 2025 年第三季度权益分派实施公告 4、本次实施分配方案距离股东会审议通过的时间未超过两个月。 二、本次实施的利润分配方案 公司2025年第三季度权益分派方案为：以公司现有总股本523,584,000股为基 数，向全体股东每10股派1.00元人民币现金（含税；扣税后，通过深股通持有股 ...

我武生物公告称，公司2025年第三季度权益分派方案已获2025年第二次临时股东会审议通过。以总股本 523,584,000股为基数，向全体股东每股派1元现金（含税），预计派发现金股利5235.84万元，不送红 股，不进行资本公积金转增股本。本次权益分派股权登记日为2026年1月19日，除权除息日为1月20日。 公司委托中国结算深圳分公司代派A股股东现金红利，部分股东现金红利由公司自行派发。 ...

Core Viewpoint - Iwubio's stock price has shown fluctuations, with a recent decline of 2.05%, while the company has experienced a year-to-date increase of 7.80% in stock value [1] Group 1: Stock Performance - As of January 12, Iwubio's stock price was 30.56 CNY per share, with a market capitalization of 16.001 billion CNY [1] - The stock has seen a 1.56% increase over the last five trading days and a 2.86% increase over the last twenty days, but a decline of 0.78% over the last sixty days [1] Group 2: Financial Performance - For the period from January to September 2025, Iwubio reported a revenue of 853 million CNY, reflecting a year-on-year growth of 16.86% [2] - The net profit attributable to shareholders for the same period was 345 million CNY, marking a year-on-year increase of 26.67% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Iwubio was 32,400, a decrease of 6.22% from the previous period [2] - The average number of circulating shares per shareholder increased by 6.63% to 14,927 shares [2] - The company has distributed a total of 9.13 billion CNY in dividends since its A-share listing, with 317 million CNY distributed in the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 5.562 million shares, an increase of 1.4524 million shares from the previous period [3] - New institutional shareholders include Jiashi Huirong Selected Stock A and Penghua Medical Technology Stock A, holding 4.7118 million shares and 4.2986 million shares, respectively [3]

Group 1 - The core viewpoint of the news is that I-Wu Biotech has shown positive financial performance with significant growth in revenue and net profit, alongside notable trading activity in its stock [2][3]. - On January 9, I-Wu Biotech's stock price increased by 2.43%, with a trading volume of 219 million yuan. The net financing purchase for the day was 1.11 million yuan, indicating strong investor interest [1]. - As of January 9, the total margin balance for I-Wu Biotech was 431 million yuan, which is 2.63% of its market capitalization, suggesting a high level of leverage compared to the past year [1]. Group 2 - For the period from January to September 2025, I-Wu Biotech reported a revenue of 853 million yuan, representing a year-on-year growth of 16.86%, and a net profit attributable to shareholders of 345 million yuan, up 26.67% [2]. - The company has distributed a total of 913 million yuan in dividends since its A-share listing, with 317 million yuan paid out in the last three years [3]. - As of September 30, 2025, the number of shareholders decreased by 6.22% to 32,400, while the average number of circulating shares per person increased by 6.63% to 14,927 shares [2].

Group 1 - The core point of the news is that I-Wu Biotech's stock price increased by 5.4% to 29.88 CNY per share, with a total market capitalization of 15.645 billion CNY as of the report date [1] - I-Wu Biotech, established on September 19, 2002, and listed on January 21, 2014, specializes in the research, production, and sales of products for the diagnosis and treatment of allergic diseases [1] - The company's main revenue sources include dust mite drops (94.17%), Artemisia flower (4.35%), skin prick liquid (1.31%), R&D services (0.12%), and others (0.05%) [1] Group 2 - Tianhong Fund has a significant holding in I-Wu Biotech, with the Tianhong National Bio-Medical ETF holding 20,400 shares, representing 0.05% of the fund's net value, ranking as the ninth largest holding [2] - The Tianhong National Bio-Medical ETF, established on January 27, 2021, has a current size of 224 million CNY and has achieved a year-to-date return of 6.03%, ranking 3691 out of 4189 in its category [2] - The fund manager, He Yuxuan, has been in position for 4 years and 190 days, with the fund's total assets amounting to 9.413 billion CNY, achieving a best return of 101.32% and a worst return of -62.42% during the tenure [3]